[Ticlopidine-induced neutropenia].
Ticlopidine (TCP) is a drug that inhibits platelet aggregation. Several studies have demonstrated its superiority over aspirin in preventing stroke and other thromboembolic diseases. However, neutropenia occurs in about 2% of TCP-treated patients, which therefore may advance to agranulocytosis, sepsis and death. They should be carefully followed with blood counts. We report 2 patients hospitalized with severe neutropenia while on TCP, despite having had regular blood counts. Their complications underline the need for patient selection and meticulous follow-up when ticlopidine is prescribed.
Balbir
A
A
Dept. of Medicine B, Bnai Zion Medicial Center, Technion Faculty of Medicine, Haifa.
Odeh
M
M
Atias
D
D
Oliven
A
A
D000368:Aged; D000369:Aged, 80 and over; D001772:Blood Cell Count; D002561:Cerebrovascular Disorders / Q000517:prevention & control; D005260:Female; D006801:Humans; D008297:Male; D009503:Neutropenia / Q000097:blood / Q000139:chemically induced* / Q000453:epidemiology; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects*; D012307:Risk Factors; D013923:Thromboembolism / Q000453:epidemiology; D013988:Ticlopidine / Q000009:adverse effects*
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine